We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+46.51%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
AUM
$163M
AUM Growth
+$48.4M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$79.1M 48.62%
3,959,440
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$27M 16.62%
2,153,092
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$24.6M 15.09%
273,077
ATXS
4
DELISTED
Astria Therapeutics
ATXS
$17M 10.42%
45,875
VBIV
5
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$9.23M 5.67%
89,701
EPIX
6
DELISTED
ESSA Pharma
EPIX
$5.83M 3.58%
106,061

Similar funds

Clarus Ventures's Q3 2016 Portfolio in Review

As of Q3 2016, Clarus Ventures held 6 positions worth $163M, up 42% from $114M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2016: portfolio turnover was 0%. Clarus Ventures opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's ten largest holdings make up 100% of its $163M portfolio in Q3 2016.
  • Clarus Ventures opened 0 new positions and closed 0 in Q3 2016.
  • Clarus Ventures's portfolio value rose 42% quarter-over-quarter to $163M.

Based on Clarus Ventures's 13F filing for Q3 2016, filed 9 Nov 2016.